down arrow

Artivion, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2289031005
USD
45.41
-0.07 (-0.15%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

45.1246.02

52 Week

21.9748.00
Valuation
Technical
Day's Volume

CASH

117.66 k

Shareholding (Mar 2025)

FII

7.33%

Held by 82 FIIs

DII

43.36%

Held by 54 DIIs

Promoter

0.00%

How big is Artivion, Inc.?

22-Jun-2025

As of Jun 18, Artivion, Inc. has a market capitalization of 1,315.53 million, classifying it as a Micro Cap company, with net sales of 390.09 million and a net profit of -21.36 million over the latest four quarters.

Market Cap: As of Jun 18, Artivion, Inc. has a market capitalization of 1,315.53 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Artivion, Inc. reported net sales of 390.09 million and a net profit of -21.36 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 276.20 million and total assets of 789.10 million.

Read More

What does Artivion, Inc. do?

22-Jun-2025

Artivion, Inc. is a medical device manufacturer specializing in implantable human tissues for cardiac surgeries, classified as a Micro Cap company with a market cap of approximately $1.32 billion. As of March 2025, it reported net sales of $99 million and a net profit of -$1 million.

Overview:<BR>Artivion, Inc. is a medical device manufacturer and processor engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 99 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,315.53 Million (Micro Cap)<BR><BR>Key Metrics:<BR>Debt Equity: 0.96 <BR>Return on Equity: -4.00% <BR>Price to Book: 4.47 <BR><BR>Contact Details:<BR>Address: 1655 Roberts Blvd NW, KENNESAW GA: 30144-3632 <BR>Tel: ['1 770 4193355', '1 646 9241769'] <BR>Fax: 1 770 4260031 <BR>Website: http://www.cryolife.com

Read More

Who are in the management team of Artivion, Inc.?

22-Jun-2025

As of March 2022, the management team of Artivion, Inc. includes Chairman and CEO James Mackin, Presiding Independent Director Ronald McCall, and independent directors Thomas Ackerman, Daniel Bevevino, Marna Borgstrom, and James Bullock. This team provides governance and strategic direction for the company.

As of March 2022, the management team of Artivion, Inc. includes the following individuals:<BR><BR>- Mr. James Mackin: Chairman of the Board, President, Chief Executive Officer, Director<BR>- Mr. Ronald McCall: Presiding Independent Director<BR>- Mr. Thomas Ackerman: Independent Director<BR>- Mr. Daniel Bevevino: Independent Director<BR>- Ms. Marna Borgstrom: Independent Director<BR>- Mr. James Bullock: Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Read More

Is Artivion, Inc. overvalued or undervalued?

20-Sep-2025

As of February 17, 2022, Artivion, Inc. has shifted from an attractive to a risky valuation due to overvaluation indicators like a Price to Book Value of 4.35 and an EV to EBITDA ratio of 32.14, coupled with low ROCE of 4.31% and negative ROE of -4.00%, despite a strong year-to-date return of 44.67%.

As of 17 February 2022, the valuation grade for Artivion, Inc. has moved from attractive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued, particularly given its Price to Book Value of 4.35 and an EV to EBITDA ratio of 32.14, which are significantly higher than industry norms. Additionally, the company's Return on Capital Employed (ROCE) stands at a low 4.31%, while its Return on Equity (ROE) is negative at -4.00%, further highlighting its financial struggles.<BR><BR>In comparison to peers, MiMedx Group, Inc. has a fair valuation with a P/E ratio of 33.09 and an EV to EBITDA of 18.90, while Embecta Corp. is also deemed risky with a P/E of 6.42 and an EV to EBITDA of 6.59. This stark contrast underscores Artivion's challenging position within the industry. Despite a strong year-to-date return of 44.67% compared to the S&P 500's 12.22%, the overall valuation metrics suggest that the stock may not be sustainable at its current price levels.

Read More

Is Artivion, Inc. technically bullish or bearish?

20-Sep-2025

As of September 5, 2025, Artivion, Inc. shows a mildly bullish trend with positive momentum from MACD and Bollinger Bands, but mixed signals from RSI and recent negative returns suggest caution.

As of 5 September 2025, the technical trend for Artivion, Inc. has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish, indicating some positive momentum. However, the weekly and monthly RSI readings are bearish, suggesting potential weakness in price momentum. The Bollinger Bands show a bullish stance on the weekly and a mildly bullish stance on the monthly, supporting the overall mildly bullish trend. Daily moving averages are bullish, which is a positive sign for short-term traders. <BR><BR>In terms of returns, Artivion has outperformed the S&P 500 year-to-date with a return of 44.67% compared to 12.22%, and over one year with a return of 65.64% compared to 17.14%. However, the recent one-week and one-month returns are negative at -2.25% and -3.48%, respectively, while the S&P 500 has gained 1.05% and 2.33% in the same periods. Overall, the current technical stance is mildly bullish, but with caution due to mixed signals from the RSI and recent performance.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a growth in Operating Profit of 58.5%, the company declared Very Positive results in Jun 25

  • The company has declared positive results in Jan 70 after 2 consecutive negative quarters
  • OPERATING CASH FLOW(Y) Highest at USD 19.66 MM
  • INTEREST COVERAGE RATIO(Q) Highest at 227.26
  • RAW MATERIAL COST(Y) Fallen by -1.86% (YoY)
2

Consistent Returns over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2,114 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.40

stock-summary
Return on Equity

-1.88%

stock-summary
Price to Book

5.04

Revenue and Profits:
Net Sales:
113 Million
(Quarterly Results - Jun 2025)
Net Profit:
1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.13%
0%
3.13%
6 Months
58.44%
0%
58.44%
1 Year
53.15%
0%
53.15%
2 Years
150.88%
0%
150.88%
3 Years
235.62%
0%
235.62%
4 Years
154.54%
0%
154.54%
5 Years
110.52%
0%
110.52%

Artivion, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Artivion, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance

Artivion, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance

Artivion, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has shown notable resilience with a 54.83% return over the past year, significantly outperforming the S&P 500. Recent evaluations reflect mixed technical indicators, highlighting its strong recovery and robust market position.

Read More
Artivion, Inc. Hits New 52-Week High of $47.69, Up 104%

Artivion, Inc. Hits New 52-Week High of $47.69, Up 104%

Artivion, Inc. has achieved a new 52-week high of USD 47.69, reflecting a significant increase in its stock price over the past year. With a market capitalization of USD 2,114 million, the company operates in a competitive sector, though it currently reports a negative return on equity.

Read More
Artivion, Inc. Hits New 52-Week High of $46.58, Up 96.65%

Artivion, Inc. Hits New 52-Week High of $46.58, Up 96.65%

Artivion, Inc. has achieved a new 52-week high, highlighting its impressive performance with a significant increase over the past year. The company, with a market capitalization of USD 2,114 million, operates in a competitive sector and currently shows a manageable debt level, despite being loss-making.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
9.46%
EBIT Growth (5y)
35.03%
EBIT to Interest (avg)
0.71
Debt to EBITDA (avg)
7.70
Net Debt to Equity (avg)
0.96
Sales to Capital Employed (avg)
0.60
Tax Ratio
5.28%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
3.37%
ROE (avg)
1.46%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.35
EV to EBIT
62.87
EV to EBITDA
32.14
EV to Capital Employed
2.71
EV to Sales
4.00
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
4.31%
ROE (Latest)
-4.00%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 60 Schemes (49.24%)

Foreign Institutions

Held by 82 Foreign Institutions (7.33%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 14.14% vs 1.75% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 360.00% vs 96.97% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "113.00",
          "val2": "99.00",
          "chgp": "14.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "16.50",
          "val2": "10.40",
          "chgp": "58.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.30",
          "val2": "7.70",
          "chgp": "-5.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5.80",
          "val2": "-3.10",
          "chgp": "-87.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1.30",
          "val2": "-0.50",
          "chgp": "360.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "97.20%",
          "val2": "50.00%",
          "chgp": "4.72%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 9.75% vs 12.81% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 56.54% vs -60.21% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "388.50",
          "val2": "354.00",
          "chgp": "9.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "51.70",
          "val2": "37.90",
          "chgp": "36.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "34.40",
          "val2": "25.40",
          "chgp": "35.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.40",
          "val2": "-28.90",
          "chgp": "108.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.30",
          "val2": "-30.60",
          "chgp": "56.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "70.70%",
          "val2": "41.80%",
          "chgp": "2.89%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
113.00
99.00
14.14%
Operating Profit (PBDIT) excl Other Income
16.50
10.40
58.65%
Interest
7.30
7.70
-5.19%
Exceptional Items
-5.80
-3.10
-87.10%
Consolidate Net Profit
1.30
-0.50
360.00%
Operating Profit Margin (Excl OI)
97.20%
50.00%
4.72%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 14.14% vs 1.75% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 360.00% vs 96.97% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
388.50
354.00
9.75%
Operating Profit (PBDIT) excl Other Income
51.70
37.90
36.41%
Interest
34.40
25.40
35.43%
Exceptional Items
2.40
-28.90
108.30%
Consolidate Net Profit
-13.30
-30.60
56.54%
Operating Profit Margin (Excl OI)
70.70%
41.80%
2.89%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 9.75% vs 12.81% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 56.54% vs -60.21% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Artivion, Inc. stock-summary
stock-summary
Artivion, Inc.
Pharmaceuticals & Biotechnology
CryoLife, Inc. (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as Surgical Sealants, BioGlue products, JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PerClot, PhotoFix, and NEXUS. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues.
Company Coordinates stock-summary
Company Details
1655 Roberts Blvd NW , KENNESAW GA : 30144-3632
stock-summary
Tel: 1 770 41933551 646 9241769
stock-summary
http://www.cryolife.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."